FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease
Journal of Pediatric Gastroenterology and Nutrition · 2025-03 · 80 (3) · 397-407
DOI: 10.1002/jpn3.12399 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 27.12.2024. Verfasst von Tania Mitsinikos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Public Health, Global Health. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
As rates of obesity rise worldwide, incidence of metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease, is increasing, worsening the burden of healthcare systems. The council of the Federation of International Societies for Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN) identified the topic of MASLD epidemiology, treatment, and prevention as a global priority issue to be addressed by an expert team, with the goal to describe feasible and evidence‐based actions that may contribute to reducing MASLD risk. The FISPGHAN member societies nominated experts in the field. The FISPGHAN council selected and appointed members of the expert team and a chair. The subtopics included in this manuscript were chosen through a consensus of the experts involved. We review the epidemiology, natural history, and screening and management. We further expand to relevant public health measures aimed at MASLD prevention, including identifying interventions that could reduce risk factors (environmental and iatrogenic), optimize maternal and newborn health, and support healthier lifestyles for older children and adolescents on a local, national, and international scale. While recognizing that various aspects of population health and public policy can shape MASLD risk, we also review what we can do on an individual level to support our patients to reduce the significant burden of this ever rising disease in pediatrics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, Los Angeles, California, USA.
- Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
- Division of Paediatric Gastroenterology, Nutrition, Hepatology and Liver Transplantation, National University of Singapore, Singapore.
- Department of Paediatrics, National University Health System, Singapore.
- Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Division of Pediatric Gastroenterology, Hospital Clinico San Borja Arriaran, Santiago, Chile.
ORCID-Profile: Tania Mitsinikos
Förderung
- None
Zitieren
APA
Mitsinikos, T., Aw, M. M., Bandsma, R., Godoy, M., Ibrahim, S. H., Mann, J. P., Memon, I., Mohan, N., Mouane, N., Porta, G., Verduci, E., & Xanthakos, S. (2025). FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition, 80(3), 397-407. https://doi.org/10.1002/jpn3.12399
Vancouver
Mitsinikos T, Aw MM, Bandsma R, Godoy M, Ibrahim SH, Mann JP, et al. FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2025;80(3):397-407. doi:10.1002/jpn3.12399
BibTeX
@article{Mitsinikos2025,
author = {Mitsinikos, Tania and Aw, Marion M and Bandsma, Robert and Godoy, Marcela and Ibrahim, Samar H and Mann, Jake P and Memon, Iqbal and Mohan, Neelam and Mouane, Nezha and Porta, Gilda and Verduci, Elvira and Xanthakos, Stavra},
title = {FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
volume = {80},
number = {3},
pages = {397--407},
doi = {10.1002/jpn3.12399}
}
EUVIMED